INNOVATE（PST0）株式概要INNOVATE Corp.は、その子会社を通じて、米国のインフラ、ライフサイエンス、スペクトラム分野で事業を展開している。 詳細PST0 ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より96.9%で取引されている リスク分析マイナスの株主資本 German市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るPST0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€14.8061.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-89m2b2016201920222025202620282031Revenue US$1.4bEarnings US$78.2mAdvancedSet Fair ValueView all narrativesINNOVATE Corp. 競合他社BAUERSymbol: HMSE:B5A0Market cap: €253.9mthyssenkrupp nucera KGaASymbol: XTRA:NCH2Market cap: €992.8mGiveSymbol: HMSE:M4NMarket cap: €17.1mAHT Syngas TechnologySymbol: DB:3SQ1Market cap: €6.8m価格と性能株価の高値、安値、推移の概要INNOVATE過去の株価現在の株価US$14.8052週高値US$16.5052週安値US$3.28ベータ2.341ヶ月の変化64.44%3ヶ月変化337.87%1年変化227.43%3年間の変化8.82%5年間の変化-55.15%IPOからの変化-70.50%最新ニュースReported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025最新情報をもっと見るRecent updatesReported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2025 Results on Aug 05, 2025INNOVATE Corp. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 12, 2025INNOVATE Corp., Annual General Meeting, Jun 12, 2025.お知らせ • Apr 17INNOVATE Corp. to Report Q1, 2025 Results on May 06, 2025INNOVATE Corp. announced that they will report Q1, 2025 results After-Market on May 06, 2025お知らせ • Feb 28INNOVATE Corp. to Report Q4, 2024 Results on Mar 31, 2025INNOVATE Corp. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025お知らせ • Jan 22INNOVATE Corp. Announces U.S. Food and Drug Administration Approved the MediBeacon TGFR for the Assessment of Kidney Function in Patients with Normal or Impaired Renal FunctionINNOVATE Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The approval of the TGFR by the FDA demonstrates proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis. The potential applications for the TGFR are numerous, and look forward to exploring them with clinicians both in the hospital and outpatient settings. The timing of FDA approval aligns well with the Fourth Quarter 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al in Kidney International with data that supports the utility of MediBeacon's patented agent Lumitrace. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within + - 30% of measured GFR (mGFR) values. For more information, including the FDA Summary of Safety and Effectiveness Data, refer to.お知らせ • Oct 17INNOVATE Corp. to Report Q3, 2024 Results on Nov 06, 2024INNOVATE Corp. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024お知らせ • Sep 04INNOVATE Regains Compliance with NYSE Minimum Price RequirementINNOVATE Corp. (the ‘Company’) announced that it has received a letter from the New York Stock Exchange (‘NYSE’) dated August 27, 2024 (the ‘Compliance Notice’), notifying the Company that it is no longer considered below the NYSE’s continued listing criterion of a minimum average share price of USD 1.00 over a 30 trading-day period (the ‘NYSE Minimum Price Requirement’). ‘The Company’s team shared that we have received notification from the New York Stock Exchange regaining listing compliance,’ said Paul Voigt, the Company’s Chief Executive Officer. ‘Regaining compliance with NYSE allows us to shift management and investor focus back on to our positive growth story’.Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.16 (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.16 (up from US$0.14 loss in 2Q 2023). Revenue: US$313.1m (down 15% from 2Q 2023). Net income: US$14.1m (up US$24.6m from 2Q 2023). Profit margin: 4.5% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2024 Results on Aug 07, 2024INNOVATE Corp. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024お知らせ • May 01INNOVATE Corp., Annual General Meeting, Jun 13, 2024INNOVATE Corp., Annual General Meeting, Jun 13, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect the four nominees identified in the accompanying proxy statement (the “Proxy Statement”), each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and to consider other matters.お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2024 Results on May 07, 2024INNOVATE Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Feb 28INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million.INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offeringお知らせ • Feb 27INNOVATE Receives Written Notice from the New York Stock Exchange Regarding Non-Compliance with the Continued Listing Standard Set in Section 802.01C of the NYSE’s Listed Company ManualOn February 26, 2024, INNOVATE Corp. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) that it was not in compliance with the continued listing standard set in Section 802.01C of the NYSE’s Listed Company Manual (‘Section 802.01C’), as the average closing price of the Company’s common stock (the ‘Common Stock’) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. The Company plans to notify the NYSE that it intends to regain compliance and is considering all available options that are in the best interests of the Company and its shareholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock.お知らせ • Feb 13INNOVATE Corp. to Report Q4, 2023 Results on Mar 04, 2024INNOVATE Corp. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024New Risk • Dec 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$127m). Earnings have declined by 53% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€92.5m market cap, or US$99.8m).お知らせ • Oct 31INNOVATE Corp. to Report Q3, 2023 Results on Nov 09, 2023INNOVATE Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023お知らせ • Sep 22INNOVATE Corp. to Cease Suzi Herbst as Chief Operating Officer on or Around October 20, 2023On September 21, 2023, INNOVATE Corp. and Ms. Suzi Herbst, the Company’s Chief Operating Officer, determined by mutual agreement that Ms. Herbst’s employment with the Company would cease on or around October 20, 2023. Ms. Herbst’s resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices.株主還元PST0DE ConstructionDE 市場7D4.2%5.0%0.6%1Y227.4%203.8%3.8%株主還元を見る業界別リターン: PST0過去 1 年間で203.8 % の収益を上げたGerman Construction業界を上回りました。リターン対市場: PST0過去 1 年間で3.8 % の収益を上げたGerman市場を上回りました。価格変動Is PST0's price volatile compared to industry and market?PST0 volatilityPST0 Average Weekly Movement16.5%Construction Industry Average Movement5.1%Market Average Movement5.9%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.8%安定した株価: PST0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: PST0の weekly volatility ( 16% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19943,663Paul Voigtinnovatecorp.comINNOVATE Corp.は子会社を通じ、米国のインフラストラクチャー、ライフサイエンス、スペクトラム分野で事業を展開している。インフラストラクチャー部門は、ビルや複合オフィスビル、ホテルやカジノ、コンベンションセンター、スポーツアリーナやスタジアム、ショッピングモール、病院、ダム、橋、鉱山、金属加工、製油所、パルプ・製紙工場、発電所などの商業・工業・インフラ建設プロジェクト向けに、構造用鋼板や大口径水道管、貯水槽の製作・架設、トラスや桁の製作、3Dビルディング・インフォメーション・モデリングや詳細設計などの産業建設、構造用鋼板、設備メンテナンスサービスを提供している。また、デジタルエンジニアリング、モデリング、詳細設計、建設、重機据付、メンテナンス、修理、据付を含む設備サービスなどのソリューションを提供し、汚染防止用スクラバー、トンネルライナー、圧力容器、ストレーナー、フィルター、セパレーター、各種カスタマイズ製品を製造している。ライフサイエンス部門は、初期の変形性膝関節症を治療する製品や、皮膚の美容・医療技術を開発している。スペクトラム部門は全米で放送局を運営している。同社は以前はHC2 Holdings, Inc.として知られていたが、2021年9月にINNOVATE Corp.に社名変更した。同社は1994年に法人化され、ニューヨーク州ニューヨークに本社を置いている。もっと見るINNOVATE Corp. 基礎のまとめINNOVATE の収益と売上を時価総額と比較するとどうか。PST0 基礎統計学時価総額€204.99m収益（TTM）-€49.07m売上高(TTM)€1.16b0.2xP/Sレシオ-4.6xPER（株価収益率PST0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PST0 損益計算書（TTM）収益US$1.34b売上原価US$1.13b売上総利益US$207.70mその他の費用US$264.10m収益-US$56.40m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-4.13グロス・マージン15.54%純利益率-4.22%有利子負債／自己資本比率-292.6%PST0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/17 20:02終値2026/06/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋INNOVATE Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sarkis SherbetchyanB. Riley Securities, Inc.
Reported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.
お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
Reported Earnings • May 20First quarter 2026 earnings released: US$1.29 loss per share (vs US$1.89 loss in 1Q 2025)First quarter 2026 results: US$1.29 loss per share (improved from US$1.89 loss in 1Q 2025). Revenue: US$364.8m (up 33% from 1Q 2025). Net loss: US$17.2m (loss narrowed 31% from 1Q 2025).
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Director Amy Wilkinson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 11, 2026INNOVATE Corp., Annual General Meeting, Jun 11, 2026.
お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2026 Results on May 14, 2026INNOVATE Corp. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • Mar 17INNOVATE Corp. to Report Q4, 2025 Results on Mar 26, 2026INNOVATE Corp. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Oct 23INNOVATE Corp. to Report Q3, 2025 Results on Nov 12, 2025INNOVATE Corp. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2025 Results on Aug 05, 2025INNOVATE Corp. announced that they will report Q2, 2025 results After-Market on Aug 05, 2025
お知らせ • Apr 29INNOVATE Corp., Annual General Meeting, Jun 12, 2025INNOVATE Corp., Annual General Meeting, Jun 12, 2025.
お知らせ • Apr 17INNOVATE Corp. to Report Q1, 2025 Results on May 06, 2025INNOVATE Corp. announced that they will report Q1, 2025 results After-Market on May 06, 2025
お知らせ • Feb 28INNOVATE Corp. to Report Q4, 2024 Results on Mar 31, 2025INNOVATE Corp. announced that they will report Q4, 2024 results After-Market on Mar 31, 2025
お知らせ • Jan 22INNOVATE Corp. Announces U.S. Food and Drug Administration Approved the MediBeacon TGFR for the Assessment of Kidney Function in Patients with Normal or Impaired Renal FunctionINNOVATE Corp. announced that the U.S. Food and Drug Administration (FDA) has approved the MediBeacon TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The approval of the TGFR by the FDA demonstrates proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis. The potential applications for the TGFR are numerous, and look forward to exploring them with clinicians both in the hospital and outpatient settings. The timing of FDA approval aligns well with the Fourth Quarter 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al in Kidney International with data that supports the utility of MediBeacon's patented agent Lumitrace. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within + - 30% of measured GFR (mGFR) values. For more information, including the FDA Summary of Safety and Effectiveness Data, refer to.
お知らせ • Oct 17INNOVATE Corp. to Report Q3, 2024 Results on Nov 06, 2024INNOVATE Corp. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
お知らせ • Sep 04INNOVATE Regains Compliance with NYSE Minimum Price RequirementINNOVATE Corp. (the ‘Company’) announced that it has received a letter from the New York Stock Exchange (‘NYSE’) dated August 27, 2024 (the ‘Compliance Notice’), notifying the Company that it is no longer considered below the NYSE’s continued listing criterion of a minimum average share price of USD 1.00 over a 30 trading-day period (the ‘NYSE Minimum Price Requirement’). ‘The Company’s team shared that we have received notification from the New York Stock Exchange regaining listing compliance,’ said Paul Voigt, the Company’s Chief Executive Officer. ‘Regaining compliance with NYSE allows us to shift management and investor focus back on to our positive growth story’.
Reported Earnings • Aug 08Second quarter 2024 earnings released: EPS: US$0.16 (vs US$0.14 loss in 2Q 2023)Second quarter 2024 results: EPS: US$0.16 (up from US$0.14 loss in 2Q 2023). Revenue: US$313.1m (down 15% from 2Q 2023). Net income: US$14.1m (up US$24.6m from 2Q 2023). Profit margin: 4.5% (up from net loss in 2Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Jul 18INNOVATE Corp. to Report Q2, 2024 Results on Aug 07, 2024INNOVATE Corp. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
お知らせ • May 01INNOVATE Corp., Annual General Meeting, Jun 13, 2024INNOVATE Corp., Annual General Meeting, Jun 13, 2024, at 11:00 US Eastern Standard Time. Agenda: To elect the four nominees identified in the accompanying proxy statement (the “Proxy Statement”), each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified; to approve, on a non-binding, advisory basis, the compensation of named executive officers; and to consider other matters.
お知らせ • Apr 28INNOVATE Corp. to Report Q1, 2024 Results on May 07, 2024INNOVATE Corp. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Feb 28INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million.INNOVATE Corp. has filed a Follow-on Equity Offering in the amount of $19 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
お知らせ • Feb 27INNOVATE Receives Written Notice from the New York Stock Exchange Regarding Non-Compliance with the Continued Listing Standard Set in Section 802.01C of the NYSE’s Listed Company ManualOn February 26, 2024, INNOVATE Corp. (the ‘Company’) received a written notice (the ‘Notice’) from the New York Stock Exchange (the ‘NYSE’) that it was not in compliance with the continued listing standard set in Section 802.01C of the NYSE’s Listed Company Manual (‘Section 802.01C’), as the average closing price of the Company’s common stock (the ‘Common Stock’) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. The Company plans to notify the NYSE that it intends to regain compliance and is considering all available options that are in the best interests of the Company and its shareholders. Pursuant to Section 802.01C, the Company has a period of six months following the receipt of the Notice to regain compliance with the minimum share price requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Common Stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the $1.00 share price rule within this period, the NYSE will initiate procedures to suspend and delist the Common Stock.
お知らせ • Feb 13INNOVATE Corp. to Report Q4, 2023 Results on Mar 04, 2024INNOVATE Corp. announced that they will report Q4, 2023 results After-Market on Mar 04, 2024
New Risk • Dec 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.5m (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-US$127m). Earnings have declined by 53% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€92.5m market cap, or US$99.8m).
お知らせ • Oct 31INNOVATE Corp. to Report Q3, 2023 Results on Nov 09, 2023INNOVATE Corp. announced that they will report Q3, 2023 results After-Market on Nov 09, 2023
お知らせ • Sep 22INNOVATE Corp. to Cease Suzi Herbst as Chief Operating Officer on or Around October 20, 2023On September 21, 2023, INNOVATE Corp. and Ms. Suzi Herbst, the Company’s Chief Operating Officer, determined by mutual agreement that Ms. Herbst’s employment with the Company would cease on or around October 20, 2023. Ms. Herbst’s resignation is not a result of any disagreement with the Company on any matter relating to its operations, policies or practices.
